Wide Ranks

IMRX

Immuneering Corporation

2.13

Top Statistics
Market Cap 66 M Forward PE -1.31 Revenue Growth 0.00 %
Current Ratio 9.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.0350 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 59 M Total Cash Per Share 2.01 Total Debt 4 M
Total Debt To Equity 6.50 Current Ratio 9.39 Book Value Per Share 3.09
All Measures
Short Ratio 119.00 % Message Board Id finmb_308350677 Shares Short Prior Month 1 M
Return On Equity -0.6181 City Cambridge Uuid e5829551-96d1-35fc-9c6d-d258079bf8f6
Previous Close 2.05 First Trade Date Epoch Utc 1 B Book Value 3.09
Beta -0.4000 Total Debt 4 M Volume 154128
Price To Book 0.6884 Fifty Two Week Low 1.00 Total Cash Per Share 2.01
Shares Short Previous Month Date 1 B Target Median Price 12.00 Audit Risk 6
Max Age 86400 Recommendation Mean 1.86 Sand P52 Week Change 0.3133
Target Mean Price 11.21 Net Income To Common -56066460 Short Percent Of Float 0.0927
Implied Shares Outstanding 31 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 412570 Average Volume10days 412570 Total Cash 59 M
Next Fiscal Year End 1 B Held Percent Insiders 0.2912 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 7
Regular Market Previous Close 2.05 Target Low Price 1.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.19 Open 2.06 Free Cashflow -31606916
State MA Dividend Yield 0.00 % Return On Assets -0.3742
Time Zone Short Name EST Board Risk 6 Trailing Eps -1.97
Day Low 2.04 Address1 245 Main Street Shares Outstanding 31 M
Compensation Risk 9 Price Hint 4 Target High Price 25.00
Website https://immuneering.com 52 Week Change -0.6753 Average Volume 5 M
Forward Eps -1.64 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 880.80 % Is_sp_500 False Regular Market Day High 2.16
Profit Margins 0.00 % Debt To Equity 6.50 Fifty Two Week High 8.89
Day High 2.16 Shares Short 2 M Regular Market Open 2.06
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0690 Operating Cashflow -50819168 Currency USD
Time Zone Full Name America/New_York Market Cap 66 M Is_nasdaq_100 False
Zip 02142 Quote Type EQUITY Industry Biotechnology
Long Name Immuneering Corporation Overall Risk 8 Regular Market Day Low 2.04
Held Percent Institutions 0.3011 Current Price 2.13 Address2 Second Floor
Enterprise To Ebitda -0.0350 Financial Currency USD Current Ratio 9.39
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 19 M Two Hundred Day Average 2.20 Governance Epoch Date 1 B
Enterprise Value 2 M Forward PE -1.31 Regular Market Volume 154128
Ebitda -60089768 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.

Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.